Apaziquone regulatory update

FDA accepted for review an NDA from Spectrum for EOquin apaziquone to treat non-muscle invasive bladder cancer (NMIBC). The PDUFA date is Dec. 11. EOquin is an analog of mitomycin C that is reduced by...